We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

CRISPR-Based Diagnostic Test Detects Pathogens in Blood Without Amplification

By LabMedica International staff writers
Posted on 17 Mar 2025
Print article
Image: The new technology offers rapid, highly sensitive detection of multi-drug-resistant bacteria (Photo courtesy of Adobe Stock)
Image: The new technology offers rapid, highly sensitive detection of multi-drug-resistant bacteria (Photo courtesy of Adobe Stock)

Rapid detection of pathogens is essential for effective disease management, especially in cases of bloodstream infections. Traditional molecular diagnostics often require nucleic acid preamplification, which increases both time and cost. Now, a new technology enables rapid and highly sensitive detection of multi-drug-resistant bacteria and other pathogens, even at low concentrations.

Researchers from the University of Illinois Grainger College of Engineering (Urbana, IL, USA) have developed a CRISPR-based diagnostic test capable of rapidly detecting low levels of pathogen genetic material in blood samples, without the need for nucleic acid amplification. In CRISPR/Cas diagnostic tests, guide RNAs bind to pathogen DNA or RNA, triggering the activation of Cas enzymes that cleave reporter nucleic acids, which fluoresce when cleaved. However, traditional CRISPR-based techniques struggle to detect pathogens at low concentrations without a preamplification step. To address this, the team developed a CRISPR-based test that eliminates the need for amplification by combining two CRISPR/Cas systems into a complex known as CRISPR-Cascade. One part of the system contains a guide RNA specific to the pathogen's nucleic acid, along with a Cas protein. When the Cas protein cleaves specially engineered nucleic acids added to the system, portions of these nucleic acids can bind to and activate a second CRISPR/Cas unit, triggering a positive feedback loop that amplifies the signal, resulting in a high signal-to-noise ratio.

The research, published in the Proceedings of the National Academy of Sciences of the United States of America (PNAS), demonstrated unprecedented sensitivity for pathogen detection. It successfully detected multi-drug-resistant Staphylococcus aureus DNA without prior amplification at concentrations significantly lower than the detection limits of tests using a single Cas enzyme. The test provided a straightforward "yes/no" result for the presence of any one of four common bloodstream pathogens in spiked samples. The findings suggest that this approach could lead to the development of highly sensitive, rapid CRISPR-based diagnostic tests capable of detecting pathogens in minutes, without the need for nucleic acid amplification.

Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Auto Clinical Chemistry Analyzer
cobas c 703
New
Vaginitis Test
Allplex Vaginitis Screening Assay

Print article

Channels

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Sekisui Diagnostics UK Ltd.